CoChat
Sign Up
Cited by 40

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

miR-137: A Novel Therapeutic Target for Human Glioma

Wang, Yajun, Chen, Riling, Zhou, Xia, Guo, Runmin, Yin, Jingwen, Li, You, Ma, Guoda·2020·Molecular Therapy Nucleic Acids
DOI 10.1016/j.omtn.2020.06.028PMC PMC7393316
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2020.06.028

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 108

  1. Morgan, 2015, The epidemiology of glioma in adults: a “state of the science” review, Neuro-oncol., 17, 623, 10.1093/neuonc/nou358 · DOI
  2. Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol., 114, 97, 10.1007/s00401-007-0243-4 · DOI
  3. Zhang, 2012, Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis, J. Neurooncol., 107, 281, 10.1007/s11060-011-0757-4 · DOI
  4. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  5. He, 2004, MicroRNAs: small RNAs with a big role in gene regulation, Nat. Rev. Genet., 5, 522, 10.1038/nrg1379 · DOI · Paper page
  6. Bier, 2013, MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1, Oncotarget, 4, 665, 10.18632/oncotarget.928 · DOI
  7. Wright, 2013, Potential Impact of miR-137 and Its Targets in Schizophrenia, Front. Genet., 4, 58, 10.3389/fgene.2013.00058 · DOI
  8. Smith, 2015, Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression, Oncotarget, 6, 12558, 10.18632/oncotarget.3726 · DOI
  9. Yang, 2015, miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma, Clin. Cancer Res., 21, 2399, 10.1158/1078-0432.CCR-14-1437 · DOI
  10. Liu, 2014, FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2, Oncotarget, 5, 5113, 10.18632/oncotarget.2089 · DOI
  11. Yin, 2014, miR-137: a new player in schizophrenia, Int. J. Mol. Sci., 15, 3262, 10.3390/ijms15023262 · DOI
  12. Soldati, 2013, Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington’s disease, J. Neurochem., 124, 418, 10.1111/jnc.12090 · DOI
  13. Warburton, 2015, Characterization of a REST-Regulated Internal Promoter in the Schizophrenia Genome-Wide Associated Gene MIR137, Schizophr. Bull., 41, 698, 10.1093/schbul/sbu117 · DOI
  14. Li, 2018, REST, not REST4, is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma, Drug Des. Devel. Ther., 12, 1363, 10.2147/DDDT.S161602 · DOI
  15. Bemis, 2008, MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines, Cancer Res., 68, 1362, 10.1158/0008-5472.CAN-07-2912 · DOI
  16. Pacheco, 2019, A VNTR Regulates miR-137 Expression Through Novel Alternative Splicing and Contributes to Risk for Schizophrenia, Sci. Rep., 9, 11793, 10.1038/s41598-019-48141-0 · DOI
  17. Silber, 2008, miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells, BMC Med., 6, 14, 10.1186/1741-7015-6-14 · DOI · Paper page
  18. Whitfield, 2002, Identification of genes periodically expressed in the human cell cycle and their expression in tumors, Mol. Biol. Cell, 13, 1977, 10.1091/mbc.02-02-0030 · DOI · Paper page
  19. Balaguer, 2010, Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis, Cancer Res., 70, 6609, 10.1158/0008-5472.CAN-10-0622 · DOI
  20. Guan, 2019, Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells, Am. J. Transl. Res., 11, 3226
  21. Qin, 2017, Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma, Leukemia, 31, 1123, 10.1038/leu.2016.325 · DOI
  22. Steponaitiene, 2016, Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis, Mol. Carcinog., 55, 376, 10.1002/mc.22287 · DOI
  23. Deng, 2016, miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1, Tumour Biol., 37, 3331, 10.1007/s13277-015-4110-y · DOI
  24. Sun, 2011, miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells, Nat. Commun., 2, 529, 10.1038/ncomms1532 · DOI
  25. Jiang, 2013, MicroRNA-137 represses Klf4 and Tbx3 during differentiation of mouse embryonic stem cells, Stem Cell Res. (Amst.), 11, 1299, 10.1016/j.scr.2013.09.001 · DOI
  26. Tarantino, 2010, miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells, FASEB J., 24, 3255, 10.1096/fj.09-152207 · DOI
  27. Yu, 2017, Knockdown of long non-coding RNA XIST increases blood-tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137, Oncogenesis, 6, e303, 10.1038/oncsis.2017.7 · DOI
  28. Wang, 2017, Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137, Am. J. Transl. Res., 9, 1845
  29. Hao, 2020, Over-expression of long noncoding RNA HOTAIRM1 promotes cell proliferation and invasion in human glioblastoma by up-regulating SP1 via sponging miR-137, Neuroreport, 31, 109, 10.1097/WNR.0000000000001380 · DOI
  30. Chen, 2020, NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/TRIM24, Cancer Biother. Radiopharm., 35, 101
  31. Du, 2019, miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4, Cell Death Dis., 10, 922, 10.1038/s41419-019-2164-2 · DOI
  32. Ying, 2017, MicroRNA-137 inhibits BMP7 to enhance the epithelial-mesenchymal transition of breast cancer cells, Oncotarget, 8, 18348, 10.18632/oncotarget.15442 · DOI
  33. Han, 2016, miR-137 suppresses the invasion and procedure of EMT of human breast cancer cell line MCF-7 through targeting CtBP1, Hum. Cell, 29, 30, 10.1007/s13577-015-0124-4 · DOI
  34. Miao, 2019, Overexpression of mircoRNA-137 inhibits cervical cancer cell invasion, migration and epithelial-mesenchymal transition by suppressing the TGF-β/smad pathway via binding to GREM1, Cancer Cell Int., 19, 147, 10.1186/s12935-019-0852-8 · DOI
  35. Dong, 2016, MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells, J. Exp. Clin. Cancer Res., 35, 132, 10.1186/s13046-016-0415-y · DOI
  36. Wang, 2018, Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137, Genet. Test. Mol. Biomarkers, 22, 333, 10.1089/gtmb.2018.0026 · DOI
  37. Chang, 2017, Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C, Cancer Lett., 402, 190, 10.1016/j.canlet.2017.06.002 · DOI
  38. Liu, 2014, MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor, Tumour Biol., 35, 9131, 10.1007/s13277-014-2177-5 · DOI
  39. Chen, 2012, miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2, Eur. J. Cancer, 48, 3104, 10.1016/j.ejca.2012.02.007 · DOI
  40. Koshkin, 2014, Profile of microRNA expression in brain tumors of different malignancy, Bull. Exp. Biol. Med., 157, 794, 10.1007/s10517-014-2669-8 · DOI
  41. Koshkin, 2014, Analysis of expression of microRNAs and genes involved in the control of key signaling mechanisms that support or inhibit development of brain tumors of different grades, Clin. Chim. Acta, 430, 55, 10.1016/j.cca.2014.01.001 · DOI · Paper page
  42. Visani, 2014, Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III, Mol. Oncol., 8, 417, 10.1016/j.molonc.2013.12.010 · DOI
  43. Liang, 2016, Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas, Oncotarget, 7, 19723, 10.18632/oncotarget.7736 · DOI
  44. Tamim, 2014, Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells, PLoS ONE, 9, e85591, 10.1371/journal.pone.0085591 · DOI
  45. Bhaskaran, 2019, The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma, Nat. Commun., 10, 422, 10.1038/s41467-019-08390-z · DOI · Paper page
  46. Channakkar, 2020, MiRNA-137-mediated modulation of mitochondrial dynamics regulates human neural stem cell fate, Stem Cells, 38, 683, 10.1002/stem.3155 · DOI
  47. Schouten, 2015, MicroRNA-124 and -137 cooperativity controls caspase-3 activity through BCL2L13 in hippocampal neural stem cells, Sci. Rep., 5, 12448, 10.1038/srep12448 · DOI
  48. Sun, 2013, Overexpressed miRNA-137 inhibits human glioma cells growth by targeting Rac1, Cancer Biother. Radiopharm., 28, 327
  49. Luo, 2018, miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma, Cell Death Differ., 25, 1457, 10.1038/s41418-017-0053-8 · DOI · Paper page
  50. van Geldermalsen, 2016, ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer, Oncogene, 35, 3201, 10.1038/onc.2015.381 · DOI
  51. Chakrabarti, 2015, Direct transfection of miR-137 mimics is more effective than DNA demethylation of miR-137 promoter to augment anti-tumor mechanisms of delphinidin in human glioblastoma U87MG and LN18 cells, Gene, 573, 141, 10.1016/j.gene.2015.07.034 · DOI
  52. Li, 2017, miR-137 acts as a tumor suppressor via inhibiting CXCL12 in human glioblastoma, Oncotarget, 8, 101262, 10.18632/oncotarget.20589 · DOI
  53. Zhang, 2017, MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression, Am. J. Transl. Res., 9, 1492
  54. Su, 2015, Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients, Tumour Biol., 36, 6333, 10.1007/s13277-015-3319-0 · DOI
  55. Sakata, 2019, MicroRNA regulating stanniocalcin-1 is a metastasis and dissemination promoting factor in glioblastoma, J. Neurooncol., 142, 241, 10.1007/s11060-019-03113-2 · DOI
  56. Sun, 2015, MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2, J. Neurooncol., 122, 481, 10.1007/s11060-015-1753-x · DOI
  57. Li, 2018, Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1, Cancer Lett., 416, 66, 10.1016/j.canlet.2017.11.033 · DOI
  58. Velasco, 2019, Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development, RNA, 25, 768, 10.1261/rna.069211.118 · DOI
  59. Kwon, 2013, Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets, Mol. Psychiatry, 18, 11, 10.1038/mp.2011.170 · DOI · Paper page
  60. Ji, 2018, FOXK1 promotes cell growth through activating wnt/beta-catenin pathway and emerges as a novel target of miR-137 in glioma, Am. J. Transl. Res., 10, 1784
  61. Li, 2013, MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L, Brain Pathol., 23, 426, 10.1111/bpa.12015 · DOI
  62. Wang, 2016, PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137, Brain Res., 1646, 441, 10.1016/j.brainres.2016.06.026 · DOI
  63. Takwi, 2014, miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells, Oncogene, 33, 3717, 10.1038/onc.2013.330 · DOI
  64. Giunti, 2019, A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation, Mol. Clin. Oncol., 10, 331
  65. Ciechomska, 2020, Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses, Adv. Exp. Med. Biol., 1202, 259, 10.1007/978-3-030-30651-9_13 · DOI
  66. Maleszewska, 2015, ). Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development, Future Oncol., 11, 2587, 10.2217/fon.15.171 · DOI
  67. Li, 2015, Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells, Mol. Cell Proteomics., 14, 316, 10.1074/mcp.M114.041905 · DOI
  68. Vire, 2006, The Polycomb group protein EZH2 directly controls DNA methylation, Nature., 439, 871, 10.1038/nature04431 · DOI · Paper page
  69. Pereira, 2010, ). Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex, Proc. Natl. Acad. Sci. USA., 107, 15957, 10.1073/pnas.1002530107 · DOI
  70. Hwang, 2014, Distinct and separable roles for EZH2 in neurogenic astroglia, Elife., 3, e02439, 10.7554/eLife.02439 · DOI
  71. Zhang, 2015, TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway, Oncogene., 34, 600, 10.1038/onc.2013.593 · DOI
  72. Lv, 2017, Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding, Cancer Res., 77, 6190, 10.1158/0008-5472.CAN-17-1388 · DOI
  73. Wood, 2008, Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint, Clin Cancer Res., 14, 7588, 10.1158/1078-0432.CCR-07-4443 · DOI
  74. Sharma, 2015, NUCKS1 is a novel RAD51AP1 paralog important for homologous recombination and genome stability, Nucleic Acids Res., 43, 9817
  75. Cheong, 2016, Identification of NUCKS1 as a putative oncogene and immunodiagnostic marker of hepatocellular carcinoma, Gene, 584, 47, 10.1016/j.gene.2016.03.006 · DOI
  76. Kikuchi, 2013, Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis, Int. J. Cancer, 132, 2295, 10.1002/ijc.27911 · DOI
  77. Gao, 2017, Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms, PLoS One, 12, e0181346, 10.1371/journal.pone.0181346 · DOI
  78. Gu, 2014, TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced beta-catenin/TCF-4 transcription, Neuro Oncol., 16, 217, 10.1093/neuonc/not194 · DOI
  79. Fortin Ensign, 2013, Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression, Front. Oncol., 3, 241, 10.3389/fonc.2013.00241 · DOI
  80. Savitch, 2006, Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome, Cancer Res., 66, 9535, 10.1158/0008-5472.CAN-06-0418 · DOI
  81. Chan, 2008, The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma, Am. J. Pathol., 173, 1828, 10.2353/ajpath.2008.080043 · DOI
  82. Innocenti, 1999, CDC25(Mm)/Ras-GRF1 regulates both Ras and Rac signaling pathways, FEBS Lett., 460, 357, 10.1016/S0014-5793(99)01374-5 · DOI
  83. Kiyono, 1999, G protein beta gamma subunit-dependent Rac-guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm), Proc. Natl. Acad. Sci. U S A, 96, 4826, 10.1073/pnas.96.9.4826 · DOI
  84. Li, 2016, Circulating microRNA-137 is a potential biomarker for human glioblastoma, Eur. Rev. Med. Pharmacol. Sci., 20, 3599
  85. Riemenschneider, 2010, MGMT promoter methylation in malignant gliomas, Target Oncol., 5, 161, 10.1007/s11523-010-0153-6 · DOI
  86. Kozaki, 2008, Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer, Cancer Res., 68, 2094, 10.1158/0008-5472.CAN-07-5194 · DOI
  87. Sun, 2019, miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene., 38, 564, 10.1038/s41388-018-0459-x · DOI
  88. Ma, 2019, LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer, J. Cell. Physiol., 234, 2880, 10.1002/jcp.27105 · DOI
  89. Cheng, 2019, Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells, Onco Targets Ther., 12, 11057, 10.2147/OTT.S228199 · DOI
  90. Zhu, 2013, MiR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1, Acta Biochim. Biophys. Sin. (Shanghai)., 45, 80, 10.1093/abbs/gms099 · DOI
  91. Mazzoleni, 2010, Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis, Cancer Res., 70, 7500, 10.1158/0008-5472.CAN-10-2353 · DOI
  92. Tunca, 2012, Olea europaea leaf extract alters microRNA expression in human glioblastoma cells., J. Cancer Res. Clin. Oncol., 138, 1831, 10.1007/s00432-012-1261-8 · DOI
  93. Al-Nedawi, 2008, Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells, Nat. Cell Biol., 10, 619, 10.1038/ncb1725 · DOI
  94. Skog, 2008, Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat. Cell Biol., 10, 1470, 10.1038/ncb1800 · DOI · Paper page
  95. Yu, 2018, Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype, Cancer Lett., 433, 210, 10.1016/j.canlet.2018.06.041 · DOI
  96. Lang, 2017, Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2, Oncol. Rep., 38, 785, 10.3892/or.2017.5742 · DOI
  97. Li, 2013, Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells, RNA Biol., 10, 1333, 10.4161/rna.25281 · DOI
  98. Salido-Guadarrama, 2014, MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer, Onco Targets Ther., 7, 1327
  99. Akers, 2013, MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development, PLoS One, 8, e78115, 10.1371/journal.pone.0078115 · DOI
  100. Wei, 2018, Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia, Neuroscience, 379, 167, 10.1016/j.neuroscience.2018.03.016 · DOI · Paper page
  101. Jiang, 2019, Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson’s disease, Brain Res., 1722, 146331, 10.1016/j.brainres.2019.146331 · DOI
  102. Wood, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.:, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  103. Hood, 2016, Post isolation modification of exosomes for nanomedicine applications, Nanomedicine (Lond), 11, 1745, 10.2217/nnm-2016-0102 · DOI
  104. Rupert, 2017, Methods for the physical characterization and quantification of extracellular vesicles in biological samples, Biochim. Biophys. Acta Gen. Subj., 1861, 3164, 10.1016/j.bbagen.2016.07.028 · DOI
  105. Zhuang, 2010, A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes, Mol. Ther., 18, 1606, 10.1038/mt.2010.105 · DOI
  106. Zhuang, 2011, Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, Mol Ther., 19, 1769, 10.1038/mt.2011.164 · DOI · Paper page
  107. Ahmed, 2015, Exosome-mediated delivery of the intrinsic C-terminus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesis, Mol Ther., 23, 255, 10.1038/mt.2014.202 · DOI
  108. Wei, 2018, Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma, Cancer Lett., 436, 10, 10.1016/j.canlet.2018.08.004 · DOI

Cited by

Sorted by citations

See all 40

Metadata

Authors
Wang, Y., Chen, R., Zhou, X., Guo, R., Yin, J., Li, Y., & Ma, G.
ORCID
Ma, Guoda
Venue
Molecular Therapy Nucleic Acids
Publisher
Elsevier BV
Published
2020-09
Volume
21
Pages
614-622
ISSN
2162-2531
DOI
10.1016/j.omtn.2020.06.028
PMC
PMC7393316
Cited by
40
References
4
Language
en
Licence
Funders
  • National Natural Science Foundation of China (81571157, 81670252, 81770034, 81873649)
  • Applied Basic Research Foundation of Yunnan Province (2019A1515011306, 2019A1515011424, 2020A1515010240)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review